Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 13 Dermatologic 7 Thoracic 3 Other hematologic neoplasm 3 Genitourinary 3 Gastrointestinal 3 Breast 3 Sarcoma 2 Plasma cell 2 Other solid neoplasm 2 CNS 2 Tumor-Agnostic 1 NET 1 Head & Neck 1 Gynecologic 1 Endocrine 1

Conditions

Interventions

pembrolizumab 95 Paclitaxel 86 Gemcitabine 84 Carboplatin 79 Surveys and Questionnaires 72 Docetaxel 61 Bevacizumab 61 Nivolumab 59 Cisplatin 59 Magnetic Resonance Spectroscopy 50 Blood Specimen Collection 50 Fluorouracil 48 Radiotherapy 47 Capecitabine 47 Irinotecan 40 Oxaliplatin 38 Erlotinib Hydrochloride 38 Biopsy 36 atezolizumab 35 Leucovorin 35 Pemetrexed 34 Standard of Care 32 Cetuximab 32 Specimen Handling 31 Trastuzumab 30 Radiosurgery 29 Ipilimumab 28 Cyclophosphamide 28 Interviews as Topic 27 olaparib 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Depsipeptides × Tumor-Agnostic × Clear all

NCT00048334 2019-12-12

Depsipeptide to Treat Thyroid and Other Advanced Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡